X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs IPCA LABS - Comparison Results

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA IPCA LABS PLETHICO PHARMA/
IPCA LABS
 
P/E (TTM) x -1.1 28.4 - View Chart
P/BV x 0.0 3.4 0.5% View Chart
Dividend Yield % 0.0 0.1 -  

Financials

 PLETHICO PHARMA   IPCA LABS
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
IPCA LABS
Mar-18
PLETHICO PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs395695 56.8%   
Low Rs31400 7.8%   
Sales per share (Unadj.) Rs604.4260.2 232.3%  
Earnings per share (Unadj.) Rs32.519.0 171.2%  
Cash flow per share (Unadj.) Rs51.333.1 155.3%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs473.6213.0 222.3%  
Shares outstanding (eoy) m34.08126.20 27.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.42.1 16.7%   
Avg P/E ratio x6.628.9 22.7%  
P/CF ratio (eoy) x4.216.6 25.1%  
Price / Book Value ratio x0.52.6 17.5%  
Dividend payout %05.3 0.0%   
Avg Mkt Cap Rs m7,26269,120 10.5%   
No. of employees `000NA13.3 0.0%   
Total wages/salary Rs m1,5967,359 21.7%   
Avg. sales/employee Rs ThNM2,477.4-  
Avg. wages/employee Rs ThNM555.2-  
Avg. net profit/employee Rs ThNM180.6-  
INCOME DATA
Net Sales Rs m20,59832,836 62.7%  
Other income Rs m386418 92.4%   
Total revenues Rs m20,98433,254 63.1%   
Gross profit Rs m2,8184,505 62.5%  
Depreciation Rs m6421,777 36.1%   
Interest Rs m1,593240 663.3%   
Profit before tax Rs m9692,905 33.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-138511 -27.1%   
Profit after tax Rs m1,1072,394 46.2%  
Gross profit margin %13.713.7 99.7%  
Effective tax rate %-14.317.6 -81.2%   
Net profit margin %5.47.3 73.7%  
BALANCE SHEET DATA
Current assets Rs m18,87719,455 97.0%   
Current liabilities Rs m11,89610,076 118.1%   
Net working cap to sales %33.928.6 118.6%  
Current ratio x1.61.9 82.2%  
Inventory Days Days3698 36.7%  
Debtors Days Days19867 295.5%  
Net fixed assets Rs m9,86120,260 48.7%   
Share capital Rs m341252 135.0%   
"Free" reserves Rs m12,33126,633 46.3%   
Net worth Rs m16,13926,886 60.0%   
Long term debt Rs m4,7062,340 201.1%   
Total assets Rs m33,14641,173 80.5%  
Interest coverage x1.613.1 12.3%   
Debt to equity ratio x0.30.1 335.0%  
Sales to assets ratio x0.60.8 77.9%   
Return on assets %8.16.4 127.3%  
Return on equity %6.98.9 77.0%  
Return on capital %12.310.8 114.2%  
Exports to sales %21.447.6 44.9%   
Imports to sales %15.214.9 102.4%   
Exports (fob) Rs m4,40215,642 28.1%   
Imports (cif) Rs m3,1364,884 64.2%   
Fx inflow Rs m4,40215,642 28.1%   
Fx outflow Rs m3,1844,884 65.2%   
Net fx Rs m1,21910,759 11.3%   
CASH FLOW
From Operations Rs m2,4373,411 71.5%  
From Investments Rs m-6,265-1,354 462.7%  
From Financial Activity Rs m2,490-1,304 -190.9%  
Net Cashflow Rs m-1,337753 -177.5%  

Share Holding

Indian Promoters % 82.7 45.9 180.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.3 11.4 37.7%  
FIIs % 5.5 25.3 21.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 17.4 43.1%  
Shareholders   10,665 36,892 28.9%  
Pledged promoter(s) holding % 85.7 2.1 4,006.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   ALEMBIC PHARMA  DISHMAN PHARMA  TTK HEALTHCARE  JUBILANT LIFE SCIENCES  BIOCON LTD  

Compare PLETHICO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Sell-Off; Sensex Slumps Over 530 Points(Closing)

Share markets in India continued their sell-off seen during the last week and ended the day deep in the red. All sectoral indices traded on a negative note.

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY18); Net Profit Up 15.6% (Quarterly Result Update)

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, IPCA LABS has posted a net profit of Rs 513 m (up 15.6% YoY). Sales on the other hand came in at Rs 8 bn (up 17.6% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA - ELDER PHARMA COMPARISON

COMPARE PLETHICO PHARMA WITH

MARKET STATS